Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, CNBC, Axios and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 6h ago.
Quick answers
Why is "Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion Bloomberg.com · 17h ago
- Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion CNBC · 17h ago
- Novartis signs $7.8 billion drug deal with Chinese startup Axios · 17h ago
- Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters · 17h ago
- Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager fiercebiotech.com · 17h ago
Topics
Related trends
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Scientists find the gene that drives T-cell exhaustion, revealing new strategy to improve immune responses
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's experimental drug sefaxersen meets its primary endpoint in a late-stage study for the autoimmune disease IgAN.
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
Telix's $2.35 billion merger with ITM signals a bold move into radiopharmaceuticals, drawing analyst optimism.